Genkyotex: Disclosure of the Total Number of Voting Rights & Shares Pursuant to Article L. 233-8 II of the French Commercial ...

Date : 09/14/2018 @ 11:45AM
Source : Business Wire
Stock : Genkyotex (GKTX)
Quote : 1.55  0.0 (0.00%) @ 11:35AM
Genkyotex share price Chart

Genkyotex: Disclosure of the Total Number of Voting Rights & Shares Pursuant to Article L. 233-8 II of the French Commercial ...

Genkyotex (EU:GKTX)
Historical Stock Chart

1 Month : From Aug 2018 to Sep 2018

Click Here for more Genkyotex Charts.

(AMF – Autorité des Marchés Financiers)

Regulatory News:

Genkyotex (Paris:GKTX) (Brussels:GKTX):

Genkyotex shares

ISIN code FR00011790542 – Euronext Paris & Brussels

Date  

Number of shares making up the share capital

  Number of voting rights

August 31,2017

  77,917,255   Theoretical number of voting rights(1): 77,917,255     Number of voting rights exercisable at a shareholders’meeting(2): 77,851,344

(1) In accordance with Article 223-111 of the AMF’s General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.(2) Less shares stripped of voting rights.

About Genkyotex

Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on the Euronext Paris and Euronext Brussels markets. A leader in NOX therapies, its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.

Genkyotex’s platform enables the identification of available small-molecules that selectively inhibit specific NOX enzymes. Genkyotex is developing a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes. The lead product candidate, GKT831, a NOX1 and NOX4 inhibitor is evaluated in a phase II clinical trial in primary biliary cholangitis (PBC, a fibrotic orphan disease) and in an investigator-initiated Phase II clinical trial in Type 1 Diabetes and Kidney Disease (DKD). A grant from the United States National Institutes of Health (U.S. NIH) of $8.9 million has been awarded to Professor Victor Thannickal at the University of Alabama at Birmingham (UAB) to fund a multi-year research program evaluating the role of NOX enzymes in idiopathic pulmonary fibrosis (IPF), a chronic lung disease that results in fibrosis of the lungs, the core component of the program will be to conduct a Phase 2 trial with the GKT831 in patients with IPF. This product candidate may also be active in other fibrotic indications. Its second product candidate, GKT771, is a NOX1 inhibitor targeting multiple pathways in angiogenesis, pain processing, and inflammation, currently undergoing preclinical testing.

Genkyotex also has a versatile platform well-suited to the development of various immunotherapies (Vaxiclase). A partnership has been established with Serum Institute of India Private Ltd (Serum Institute) and could generate approximately €150 million in future revenues for Genkyotex, before royalties on sales.

For further information, please go to www.genkyotex.com

Genkyotex

Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V:us D:20180925 23:06:58